Epithelioid granulomatous lesions express abundant programmed death ligand-1 (PD-L1): a discussion of adverse events in anti-PD-1 antibody-based cancer immunotherapy.
Epithelioid granulomatous lesions express abundant programmed death ligand-1 (PD-L1): a discussion of adverse events in anti-PD-1 antibody-based cancer immunotherapy.
复制标题
上皮样肉芽肿病变表达丰富的程序性死亡配体-1 (PD-L1)：基于抗 PD-1 抗体的癌症免疫治疗中不良事件的讨论。
DOI：
10.1080/21645515.2020.1870364
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Torigoe T.
中科院分区：
文献类型：
--
作者：
Kubo T;Hirohashi Y;Tsukahara T;Kanaseki T;Murata K;Hasegawa T;Torigoe T.
免疫系统通常被称为一把双刃剑，因为癌症免疫和过敏/自身免疫之间有着千丝万缕的联系。有趣的是，已经报道了越来越多的病例，其中PD-1阻断引发结核病（TB）恶化，这是一种由细菌感染引起的器官侵袭性肉芽肿性疾病。因此，TB的恶化现在被认为是纳武利尤单抗和派姆单抗的严重不良反应。在这封信中，我们报告了PD-L1在结核、结节病、克罗恩病和异物肉芽肿的上皮样肉芽肿性病变中的强表达。此外，我们还讨论了基于抗PD-1抗体的癌症免疫治疗后结核病的加重。
The immune system is often called a double-edged sword, due to the inextricable link between cancer immunity and allergy/autoimmunity. Intriguingly, a growing number of cases have been reported in which PD-1 blockade triggers the exacerbation of tuberculosis (TB), an organ-invasive granulomatous disease caused by bacterial infection. As a result, the exacerbation of TB is now considered a severe adverse effect of nivolumab and pembrolizumab. In this letter, we report the strong expression of PD-L1 in epithelioid granulomatous lesions in tuberculosis, sarcoidosis, Crohn’s disease, and foreign body granuloma. In addition, we discussed the exacerbation of tuberculosis after anti-PD-1 antibody-based cancer immunotherapy.